Publication | Closed Access

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination

Highdose MelphalanOncologyMedicineImmunologyImmune Checkpoint InhibitorPharmacotherapyNk-1 Receptor-antagonist AprepitantAnti-cancer AgentCancer TreatmentTriple Antiemetic CombinationPharmacologyChemotherapyCancer Research